INTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES. Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí
|
|
- Anabel Octavia Alexander
- 6 years ago
- Views:
Transcription
1 INTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí
2 STRATEGIES FOR CRLM LIVER METASTASES Extended indications Resectable 20-30% 10-20% Non resectable 80-90% 70-80% Surgery 20-40% Optimizing Chemotherapy Loco-regional therapies 2
3 3
4 80 PERCUTANEOUS TREATMENTS TIMELINE 90 RADIOEMBOLIZATION (TARE) HAI 80 TAE 85 TACE-LIPIODOL in HCC >90 TACE HCC highly developed >2010 DEBIRI-M1 INTRAARTERIAL CHEMOTHERAPY HAI TAE c-tace TACE DEBIRI RADIOEMBOLIZATION
5 80 PERCUTANEOUS TREATMENTS TIMELINE 90 RADIOEMBOLIZATION (TARE) HAI 80 TAE 85 TACE-LIPIODOL in HCC >90 TACE HCC highly developed >2010 DEBIRI-M1 INTRAARTERIAL CHEMOTHERAPY HAI TACE DEBIRI
6 1. Colorectal cancer (CRC): Liver is ussually the 1st site of mets. Hematogenic spread: Portal vein liver lung other organs 2. Vascularization: CRLM: Almost exclusively by hepatic artery Normal liver: Preferentially by portal vein 3. Increased exposure to chemotherapy of liver VASC. METS HEPATIC ARTERY >95% HEPATIC ARTERY PORTAL VEIN NORMAL LIVER PORTAL VEIN 80% HEPATIC ARTERY 20%
7 1. Placement of a permanent catheter in gastroduodenal artery Surgical vs.endovascular 2. Oclusion of gastrointestinal branches with coils 3. Redistribution of hepatic flow through common hepatic artery TOTAL PARENQUIMAL SATURATION RIGTH AND LEFT HEPATIC A. LEFT GASTRIC A. GASTRODUODENAL A. COMMON HEPATIC A.
8 HEPATICO-MESENTERIC TRUNK
9
10 28 patients ORR: 64% 5 Surgical resections PFS: 27 months HAI oxaliplatin and IV LV5FU2 is feasible, safe, and shows promising activity after systemic chemotherapy failure, allowing surgical resection of initially unresectable CRLM in 18% of patients.
11 16 patients, with missing metastases( ) 12 patients received oxiloplatin HAI pre or post-operative. In 10 (61%), missing LMs not reapear Mean follow-up 51 months (24-90) 3-year survival: 94% Adjuvant HAI was significantly correlated with the definitive eradication of missing LMs (P <.01).
12 Kemeny et al., 2009 N: 49. Sistemic chemotherapy(irinotecan/oxaliplatin) + HAI(FUDR) 73% >5 lesions, 98% Bilobar disease, 86% >6 segments afected Results: ORR 92% 47% Resection (57% in chemo-naive) Median survival 50,8 M 35 M
13 Diagnosis of CRLM Resectable Unresectable Neo-adjuvant/ Pre-operative therapy Potentially resectable HAI First-line HAI Surgery Adjuvant therapy Missing metastases HAI Second-line HAI Third-line HAI Fourth-line
14 Chemoembolization with drug-eluting beads preloaded with irinotecan Round and calibrate particulate of PVA Hidrophilic coating µ DC Bead before Irinotecan loading More recently DEBIRI M 1 ( µ) Max. Load 50mg /ml Irinotecan Loading by ion exchange Pharmacy preparation Time to complete charge about 2 hours Charged spheres stability 14 days DC Bead after Irinotecan loading
15 PROOF OF CONCEPT Intraarterial Debiri produce a High intratumoral levels, and negligible plasmatic levels, with a constant and sustained release of Irinotecan. Forni et al. 1994
16 Unresectable, liver only or liver-dominant metastases With no response to chemotherapy. <60% hepatic involvement Portal patency ECOG < 2 Expected survival>3 meses Liver tests INR <1.3 Tot. Bil. <2mg/100ml Serum transaminases (AST & ALT) 5 x ULN Special attention Previous history of biliary tree surgery.
17 1 vial per session (100mg Irinotecan) Lobar embolization prefered* PARAGON II STUDY * Lobar injection of DEBIRI should be prefered to a selective injection because some nodules are not visible at imagery and therefore may not be treated if the catheterization is too selective Jones et al. HPB 2012
18 1 vial per session (100mg Irinotecan) Lobar embolization prefered* Unilobar disease 2 treatments at 3-4 weeks interval. Bilobar disease 4 treatments at.2-3 weeks intervals
19 1. PROSPECTIVE STUDY PHASE II. TACE DEBIRI in patients with CRLM, refractory to chemotherapy. (n=82 ) 185 treatments SAFETY AND TOLERABILITY MAJOR COMPLICATIONS: 0% (1 caso de pancreatitis). MINOR COMPLICATIONS: - Post-embolitzation syndrome: Fever 80% Abdominal pain, 40% Hypertension 12% Nausea 27% Asthenia 70% Diarrhea 14% RESULTS ORR (mrecist): 80% >50% CEA 75%. ALIBERTI : TACE using irinotecan-eluting beads is well tolerated and a feasible and effective PALLIATIVE therapy in pretreated patients
20 Fiorentini et al. Anticancer research PROSPECTIVE TRIAL PHASE III. TACE DEBIRI (36) vs. FOLFIRI (38) (n=74) 2 years SURVIVAL RR (mrecist) ACUTE TOXICITY LATE TOXICITY IMPROVEMENT QOL COST (Euros) DEBIRI 56% 78% 80% 25% 65% 4500 FOLFIRI 32% 20% 20% 70% 25% Procedures 60% 50% 40% 30% 20% DEBIRI FOLFIRI 56% DEBIRI 22 months (95% CI 21-23) FOLFIRI15 months (95% CI 12-18) p = (log rank test) 10% 0% 32% Pain Vomiting and Nausea Fever Asthaenia Diarrhoaea Leucopaenia Anemia Alopecia DEBIRI could reach the goal to increase MEDIAN SURVIVAL by 43% at 2 years compared to FOLFIRI chemotherapy.
21 3. Randomized phase II Clinical Trial of Irinotecan Drug Eluting Beads with simultaneous FOLFOX/ Bevacizumab for patients with irressecable colorectal liver-limited metastasis. Prospective, multiinstitutional, phase II clinical trial. N=70 patients 30 Patients Control arm FOLFOX +/- Bevacizumab vs. 40 ( ) patients Treatment arm FOLFOX- DEBIRI +/- Bevacizumab Chemo-naive population, Liver dominant disease 80% Liver replacement by tumor 60% Standard chemotherapy at day 0, 14 and 7, 21 for DEBIRI. Bevacizumab to the discretion of medical oncologist Robert Martin C. G. Cancer 2015
22 No significant diferences about dose delay, dose-limiting toxicity No significant diferences between treatment groups among chemotherapy-specific adverse events Improvement hepatic PFS (17 mo vs. 12 mo.) No diferences in overall PFS. More durable ORR in pacients downsized to resection (35% vs. 6%) DEBIRI represents a less toxic, less expensive, and more convenient treatment alternative to other regional hepatic artery therapies. Robert Martin C. G. Cancer 2015
23 Adjuvant treatment after hepatic resection. Decrease recurrences Missing metastases First line treatment in unresectable CRLM patient. Convert to resectability. In further line as a salvage treatment. Allow chemotherapy holidays.
24 HAI performed at Highly specialized centers, can improve survival. Need for high skilled team. DEBIRI represents a simple, effective, and confident technique in delivering a high intratumoral dose of Irinotecan. Good tolerance, low systemic toxicity, and low rate morbidity in suitable candidates. Effective in 2 ond line and further. Response rate 70-80% in no responders DEBIRI in combination with systemic chemotherapy in first line therapy are promising, but Prospective clinical data are lacking, and outcomes relating to survival have yet to be established in large-scale Phase III trials.
25 Thank You!
Role of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer
Role of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer M Ducreux, MD, PhD Gustave Roussy Villejuif, FRANCE M Ducreux is a consultant to Biocompatibles
More informationLIVER DIRECTED THERAPIES FOR PATIENTS WITH UNRESECTABLE METASTASES
LIVER DIRECTED THERAPIES FOR PATIENTS WITH UNRESECTABLE COLORECTAL CANCER LIVER METASTASES Jaime R. Merchan, MD, MMSc Associate Professor of Medicine Division of Hematology-Oncology University of Miami
More informationTips and tricks. Camillo Aliberti, Massimo Tilli
Tips and tricks Camillo Aliberti, Massimo Tilli Unit of Oncological Diagnostic and Interventional Radiology, Delta Hospital AUSL Ferrara, Ferrara Italy camy.ali@libero.it mtilli72@libero.it Intra-arterial
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationClinical Study Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer
Gastroenterology Research and Practice Volume 5, Article ID 75, 6 pages http://dx.doi.org/.55/5/75 Clinical Study Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal
More informationChemosaturation: Indication, Technique and Outcome
Chemosaturation: Indication, Technique and Outcome Thomas J Vogl, S Koch, B Gebauer, W Willinek, C Engelke, R Bruening, F Wacker, A Enk I D I R: Institute of Diagnostic and Interventional Radiology Goethe
More informationAintree University Hospital
Aintree University Hospital Liverpool, UK Evolving role of DEBIRI with DC Bead - TACE in mcrc Hassan Z Malik MD FRCS Consultant Hepatobiliary Surgeon Hassan Z Malik is a consultant to Biocompatibles UK
More informationDC Bead Chemoembolisation for the Treatment of Primary [DEBDOX ] and Secondary [DEBIRI ] Liver Cancer Review of Published Clinical Data
DC Bead Chemoembolisation for the Treatment of Primary [DEBDOX ] and Secondary [DEBIRI ] Liver Cancer Review of Published Clinical Data Professor Thomas J Vogl Goethe University Hospital Frankfurt-am-Main,
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationHelping you access curative therapies for liver cancer patients
Metastatic colorectal cancer (mcrc) Helping you access curative therapies for liver cancer patients Biocompatibles Excellence in Interventional Oncology Biocompatibles UK Ltd is a BTG International group
More informationMultidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers
Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network
More informationTRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD
UNIVERSITY OF PRETORIA STEVE BIKO ACADEMIC HOSPITAL SOUTH AFRICA TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD 1 INTRODUCTION Hepatic
More informationCOMPARING Y90 DEVICES
COMPARING Y90 DEVICES William S Rilling MD, FSIR Professor of Radiology and Surgery Director, Vascular and Interventional Radiology Medical College of Wisconsin DISCLOSURES Research support : Siemens,
More informationState of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options
State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options Ioannis S. Hatzaras, MD, MPH, FACS Assistant Professor of Surgery Division of Surgical Oncology
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationRadiofrequency Ablation versus Microwave Ablation in HCC and Liver Metastases
Radiofrequency Ablation versus Microwave Ablation in HCC and Liver Metastases Thomas J. Vogl, B. Panahi, N. Nour-Eldin I D I R: Institute of Diagnostic and Interventional Radiology Goethe University Frankfurt,
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationRole of SIRT Beyond First Line Therapy in Colorectal Cancer. Dr Toh Han Chong Division of Medical Oncology National Cancer Centre Singapore
Role of SIRT Beyond First Line Therapy in Colorectal Cancer Dr Toh Han Chong Division of Medical Oncology National Cancer Centre Singapore MILESTONES IN THE TREATMENT OF COLON CANCER SIR-Spheres microspheres
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationEPIDEMIOLOGY. Long established risk factors for CCA: hepatobiliaryflukes, PSC, biliary tract cysts, epatolithiasis.
EPIDEMIOLOGY Intrahepatic cholangiocarcinoma(icc) is the second most common (15%) primary liver cancer after hepatocellular carcinoma (HCC), with a rate of about 2.1/100,000 people per year in western
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationTechniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D.
Techniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D. Department of Surgery Grand Rounds University of Kentucky January 15, 2014 Metastatic Colorectal Cancer (CRC)
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationTreatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
More informationRegional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine
Regional Therapy for Metastatic Neuroendocrine Tumors Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Introduce regional therapy for mnet Arterial therapies Injection
More informationHepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization
Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization JP King PGY2 May 22, 2015 Neuroendocrine Tumor (NET) WHO Classification Location
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More informationP < vs. 5FU/LV LD 0% 60.0% 3.6 months P < P = 0.113
in Colorectal Cancer The following summarizes the key data within the broad clinical platform supporting the use of SIR-Spheres Y-9 resin microspheres in the treatment of liver metastases arising from
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its
More informationIMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS
UnitedHealthcare Commercial Medical Policy IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS Policy Number: 2018T0445O Effective Date: February 1, 2018 Table of Contents Page INSTRUCTIONS
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More informationKEYWORDS: hepatic artery therapy, irinotecan, liver-directed therapy, liver-dominant metastatic colorectal cancer, metastatic colon cancer.
Randomized Controlled Trial of Irinotecan Drug-Eluting Beads With Simultaneous FOLFOX and Bevacizumab for Patients With Unresectable Colorectal Liver-Limited Metastasis Robert C. G. Martin II, MD, PhD
More informationLIVER SURGERY 2. Case 1. Med 5 Refresher Course (Surgery) 2013/14. Dr Sunny Cheung
LIVER SURGERY 2 Med 5 Refresher Course (Surgery) 2013/14 24 Jun 2013 Dr Sunny Cheung Case 1 50/M Sudden onset of epigastric pain Abdominal distension Confused HR 120 BP 80/50 Haemocue = 8 What should you
More informationManagement of Colorectal Liver Metastases
Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver
More informationIntra arterial ports: complex, demanding but rewarding
Intra arterial ports: complex, demanding but rewarding Gregory Amouyal, MD. Marc sapoval, MD. PhD. Olivier Pellerin, MD. MsC. Interventional Radiology Department, hospital European Georges Pompidou, Paris,
More informationLiver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties
Patient Education Treatment options This handout describes different kinds of tumors that form in the liver and how they are treated. About the Liver Your liver is the largest organ in your abdomen. It
More informationDescription. Section: Therapy Effective Date: July 15, 2014 Subsection: Therapy Original Policy Date: June 7, 2012 Subject: Page: 1 of 23
Last Review Status/Date: June 2014 Page: 1 of 23 Description Radioembolization (RE), referred to as selective internal radiation therapy or SIRT in older literature, is the intra-arterial delivery of small
More informationRuolo della interventistica per le secondarietà epatiche e di altre sedi
Ruolo della interventistica per le secondarietà epatiche e di altre sedi Giancarlo Bizzarri Dipartimento di Diagnostica per Immagini e Radiologia Interventistica Ospedale Regina Apostolorum, Albano Laziale
More informationtreatment options for primary liver malignancies and metastatic disease
State of the art treatment options for primary liver malignancies and metastatic disease Peter Huppert Prof. of Radiology and Neuroradiology Klinikum Darmstadt Certified Vascular and Oncologic Center Disclosure
More informationIMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS
UnitedHealthcare Oxford Clinical Policy IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS Policy Number: CANCER 036.11 T2 Effective Date: May 1, 2018 Table of Contents Page INSTRUCTIONS
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationLiver surgery for colorectal liver metastases. Keith Roberts, Consultant Liver Transplant and Liver/Pancreas Surgeon University Hospitals Birmingham
Liver surgery for colorectal liver metastases Keith Roberts, Consultant Liver Transplant and Liver/Pancreas Surgeon University Hospitals Birmingham Introduction: what do we do? UHB Liver Unit: Liver resections
More informationRadioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases
Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora silentio» Malignant
More informationHow to deal with synchronous primary and liver metastases
How to deal with synchronous primary and liver metastases Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB) Department of Surgery.
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationResection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy
Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy Dr Chan Chung Yip MBBS, M.Med(Surgery), MD, FAMS, FRCSEd Senior Consultant and Head Department of Hepatopancreatobiliary
More informationTransarterial Chemoembolization in Neuroendocrine Liver Metastasis
Transarterial Chemoembolization in Neuroendocrine Liver Metastasis Ricardo D. Garcia-Monaco, MD, PhD, FSIR; Andres Alejandro Kohan, MD From Vascular and Interventional Radiology, Department of Radiology,
More informationSIR-Spheres: Des essais cliniques à la pratique courante
SIR-Spheres: Des essais cliniques à la pratique courante Un focus sur le traitement du mcrc en échappement thérapeutique Dr. Michaël Vouche, MD. PhD. Université Libre de Bruxelles Institut Jules Bordet
More informationLiver Directed Therapy for Hepatocellular Carcinoma
Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationMEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015
Supported by an Independent Educa1onal Grant from MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015 BY DR. GUILLEM ARGILES, BARCELONA, SPAIN Cancers of the Lower GI Tract RAISE: A RANDOMIZED, DOUBLE-BLIND,
More informationRadioembolization for Primary and Metastatic Tumors of the Liver
Radioembolization for Primary and Metastatic Tumors of the Liver Policy Number: 8.01.43 Last Review: 8/2017 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationRadiofrequency Ablation of Primary or Metastatic Liver Tumors
Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationSystemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationThe Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
More informationRadioembolization for Primary and Metastatic Tumors of the Liver
Page: 1 of 28 Last Review Status/Date: September 2015 Description Radioembolization (RE), also referred to as selective internal radiotherapy (SIRT), is the intra-arterial delivery of small beads (microspheres)
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationRadioembolization for Primary and Metastatic Tumors of the Liver
Radioembolization for Primary and Metastatic Tumors of the Liver Policy Number: 8.01.43 Last Review: 8/2018 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationSurgical Metabolism Section, Surgery Branch, NCI, Bethesda, MD Division of Surgical Oncology, University of Maryland, Baltimore, MD
High Dose Intra-Arterial Melphalan Delivered via Percutaneous Hepatic Perfusion (PHP) for Patients with Unresectable Hepatic Metastases from Primary Neuroendocrine Tumors. James F. Pingpank, Richard E.
More informationY-Microspheres Radioembolization for Selective Internal Radiation Therapy of Primary and Metastatic Cancer in the Liver
90 Y-Microspheres Radioembolization for Selective Internal Radiation Therapy of Primary and Metastatic Cancer in the Liver Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora
More informationCOLORECTAL CANCER CASES
COLORECTAL CANCER CASES Case #1 Case #2 Colorectal Cancer Case 1 A 52 year-old female attends her family physician for her yearly complete physical examination. Her past medical history is significant
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationJose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma
Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre Evolution of liver resection Better understanding
More informationTrattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica
Trattamento chirurgico delle lesioni epatiche secondarie difficili Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica What does it mean difficult lesions? Diagnosis Treatment Small size Unfit
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationSIRT in Neuroendocrine Tumors
SIRT in Neuroendocrine Tumors Marnix G.E.H. Lam, MD PhD Professor of Nuclear Medicine AVL Amsterdam UMC Utrecht ENETS Center of Excellence, The Netherlands Disclosure of speaker s interests Consultant
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationNHS England. Cedar on behalf of NHS England Specialised Commissioning
NHS England Evidence review: selective internal radiation therapy (SIRT) with ytrrium-90 microspheres for unresectable, liver-only or liver-dominant metastatic colorectal carcinoma who are chemotherapyrefractory
More informationTranscatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Selective internal radiation therapy (SIRT) in the treatment of chemotherapy refractory and intolerant, unresectable metastatic colorectal cancer (Adults) Reference:
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More information